News

Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed…

2 years ago

Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of…

2 years ago

BrightInsight Adds Xealth, Woebot Health and Claritas Rx to the BrightInsight Ecosystem

Companies Will Collaborate to Drive Digital Innovation, Adoption and EngagementSAN JOSE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc.,…

2 years ago

TOMI Environmental Receives Additional Orders for Custom Engineered Systems From Multinational Pharmaceutical Company

A Case Study -The Expansion of SteraMist Products in a Multinational Pharmaceutical CompanyFREDERICK, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) --…

2 years ago

WIMI Hologram Academy: The Application of Virtual Reality technology in pulmonary function rehabilitation in COVID-19 patients

HONG KONG, Sept. 27, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,…

2 years ago

Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD

ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working…

2 years ago

Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S.

CHICAGO and LOUGHBOROUGH, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company…

2 years ago

Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing supports…

2 years ago

Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors

REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company…

2 years ago

PaxMedica, Inc. Provides Corporate Update After IPO

-PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer- -Second Independent Director, Dr. John…

2 years ago